

INFANT NUTRITION

FEEDING THE FUTURE 2026



PLATINUM SPONSOR



THE INSIDE MATTERS

Introducing our Platinum Sponsor,
FrieslandCampina Ingredients

FrieslandCampina Ingredients is a global leader in proteins and prebiotics, providing innovative, nutritious, ingredients that help people get the most out of life, always. With decades of expertise in Early Life Nutrition, the company supports brands around the world in developing specialised solutions for infants, toddlers and young children during the most formative stages of growth. In all phases it is critical that optimum nutrition is available.

The company is committed to developing and providing nutrition when breastfeeding is not an option.

Backed by science and grounded in a long-standing commitment to quality, customers can rely on FrieslandCampina Ingredients to create the best solutions – designed to increase immunity, improve gut health, and fuel growth and brain development – addressing key areas of parental priority.

During the conference, FrieslandCampina Ingredients will share perspectives on:

- Key trends shaping the infant and young child nutrition landscape
- How prebiotics, bioactive proteins and other nutritional ingredients can support gut health and immunity
- Opportunities for brands to differentiate through purposeful innovation in Early Life Nutrition

As a trusted partner to global nutrition brands, FrieslandCampina Ingredients looks forward to contributing valuable insights to this year's event.

INFANT NUTRITION

FEEDING THE FUTURE 2026



PLATINUM SPONSOR



Morinaga Nutritional Foods (Asia Pacific) Pte. Ltd. is a wholly owned subsidiary of Morinaga Milk Industry Co., Ltd., Japan.

Based in Singapore, we support Southeast Asia and Oceania with functional ingredients for infant and early-life nutrition.

Our probiotic portfolio is backed by Morinaga Milk's long-standing expertise in dairy science and human-residential bifidobacteria research, and is supported by published clinical and scientific studies, including research in infant populations and HMO utilization. Key strains include BB536, M-16V and M-63, with selected strains listed for use in infant and toddler food applications in China and other key markets.

During our session we will present, Bridging Early-Life Microbiota Gaps with Bifidobacterium infantis M-63: From Colonisation to Developmental Outcomes.

Many infants miss the opportunity to establish an optimal gut microbiota during early life, potentially impacting healthy development. Our presentation explores how Bifidobacterium infantis M-63 helps bridge this gap by promoting a bifidobacteria-dominant microbiota, supporting gut health and positive developmental outcomes. Drawing on evidence from both clinical trials and real-world studies, the session will highlight the growing role of targeted microbiota support in early-life nutrition.